{"schema_version":"1","generated_at":"2026-11-21T15:58:31.711Z","data_as_of":null,"url":"https://www.findmykol.com/kol/charles-kuzma","json_url":"https://www.findmykol.com/kol/charles-kuzma/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"charles-kuzma","name":"Charles Kuzma","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Southeast Clinical Oncology Research Consortium","institution_url":"https://www.findmykol.com/institution/southeast-clinical-oncology-research-consortium","city":"Pinehurst","state":"NC","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Charles Kuzma is an Oncology physician affiliated with Southeast Clinical Oncology Research Consortium. OpenAlex indexes 37 publications with 4,049 citations (h-index 17).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":37,"cited_by_count":4049,"h_index":17,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":52,"program_years":{"first":2021,"last":null},"rows_total":142,"shown":3,"withheld":139,"rows":[{"payer":"Amgen","program_year":2025,"amount_usd":289595.05,"payment_count":8},{"payer":"Pfizer","program_year":2025,"amount_usd":274143.4,"payment_count":20},{"payer":"Mirati Therapeutics","program_year":2025,"amount_usd":36195.75,"payment_count":2}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":8,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":55.3,"classes_total":6,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":17.8,"drugs":[{"name":"Letrozole","share_pct":65.9},{"name":"Anastrozole","share_pct":34.1}],"max_beneficiaries":35},{"class":"Thalidomide Analog","setting":"prescribed","share_pct":14.9,"drugs":[{"name":"Revlimid","share_pct":62.8},{"name":"Lenalidomide","share_pct":28.5},{"name":"Pomalyst","share_pct":8.8}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":15.5,"classes_total":5,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":7.3,"drugs":[{"name":"Ondansetron Hcl","share_pct":71.6},{"name":"Ondansetron Odt","share_pct":28.4}],"max_beneficiaries":null},{"class":"Potassium supplement","setting":"prescribed","share_pct":3.1,"drugs":[{"name":"Potassium Chloride","share_pct":100}],"max_beneficiaries":11}]},{"area":"Nervous system","share_pct":11,"classes_total":3,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":5.6,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":11},{"class":"Phenothiazine","setting":"prescribed","share_pct":3.9,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":29}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":37,"shown":5,"withheld":32,"matched_by":"OpenAlex author record","recent":[{"title":"Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-25-01569","status":"verified"},{"title":"Abstract RF2-02: Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer","year":2026,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs25-rf2-02","status":"verified"},{"title":"Abstract PS3-11-04: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with HER2+ Breast Cancer - Results from the ATOP Study","year":2026,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs25-ps3-11-04","status":"verified"},{"title":"Comprehensive Patient-Reported Outcomes from NRG Oncology/Alliance LU005: A Randomized Trial of Chemoradiation With or Without Atezolizumab in Limited-Stage SCLC","year":2026,"journal":"Journal of Thoracic Oncology","source_url":"https://doi.org/10.1016/j.jtho.2026.104117","status":"verified"},{"title":"Abstract PS3-01-30: Change in mammographic density (MD) with metformin use: Alliance A211201, A companion study to NCIC study MA.32","year":2026,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs25-ps3-01-30","status":"verified"}],"source":"works"},"similar":[{"name":"Michael Messino","slug":"michael-messino","institution":"Southeast Clinical Oncology Research Consortium","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/michael-messino","json_url":"https://www.findmykol.com/kol/michael-messino/profile.json"},{"name":"Mohan Thakuri","slug":"mohan-thakuri","institution":"Southeast Clinical Oncology Research Consortium","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/mohan-thakuri","json_url":"https://www.findmykol.com/kol/mohan-thakuri/profile.json"},{"name":"Patricia Zekan","slug":"patricia-zekan","institution":"Southeast Clinical Oncology Research Consortium","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/patricia-zekan","json_url":"https://www.findmykol.com/kol/patricia-zekan/profile.json"},{"name":"Navin Anthony","slug":"navin-anthony","institution":"Southeast Clinical Oncology Research Consortium","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/navin-anthony","json_url":"https://www.findmykol.com/kol/navin-anthony/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":139,"publications":32}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}